we�re at the beginning of a new breakout level of truth. it�s called independent media.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.". plemmons added, "particularly in a time when mental health resources for children appear to be static, and woefully scarce across the u.s".
.
another new drug in the migraine pipeline is lasmiditan. it works the same way as triptans. but unlike the triptans, it doesn't constrict
.
.
.